Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Aclaris Therapeutics (ACRS) over the last 11 years, with Dec 2024 value amounting to $74.5 million.

  • Aclaris Therapeutics' Cash from Financing Activities fell 13936.36% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 1424940.00%. This contributed to the annual value of $74.5 million for FY2024, which is 179.10% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Cash from Financing Activities of $74.5 million as of FY2024, which was up 179.10% from $26.7 million recorded in FY2023.
  • Aclaris Therapeutics' Cash from Financing Activities' 5-year high stood at $225.1 million during FY2021, with a 5-year trough of $18.4 million in FY2020.
  • Its 3-year average for Cash from Financing Activities is $58.0 million, with a median of $72.9 million in 2022.
  • As far as peak fluctuations go, Aclaris Therapeutics' Cash from Financing Activities soared by 1,124.97% in 2021, and later tumbled by 67.62% in 2022.
  • Over the past 5 years, Aclaris Therapeutics' Cash from Financing Activities (Yearly) stood at $18.4 million in 2020, then soared by 1,124.97% to $225.1 million in 2021, then tumbled by 67.62% to $72.9 million in 2022, then plummeted by 63.35% to $26.7 million in 2023, then skyrocketed by 179.10% to $74.5 million in 2024.